Relevant bibliographies by topics / Janssen

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Janssen'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Janssen.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Janssen"

1

Alphs, Larry. "JANSSEN." Schizophrenia Research 136 (April 2012): S60. http://dx.doi.org/10.1016/s0920-9964(12)70222-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Watson, R. "Paul Janssen." BMJ 327, no. 7426 (November 29, 2003): 1290. http://dx.doi.org/10.1136/bmj.327.7426.1290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Oransky, Ivan. "Paul Janssen." Lancet 363, no. 9404 (January 2004): 251. http://dx.doi.org/10.1016/s0140-6736(03)15357-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bruntink, Rob. "Daisy Janssen." Pallium 19, no. 1 (February 2017): 30–32. http://dx.doi.org/10.1007/s12479-017-0015-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Launay, Françoise, and Peter D. Hingley. "Jules Janssen's ‘Revolver Photographique’ and its British Derivative, ‘the Janssen Slide’." Journal for the History of Astronomy 36, no. 1 (February 2005): 57–79. http://dx.doi.org/10.1177/002182860503600107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Janssen??s risperidone." Inpharma Weekly &NA;, no. 836 (May 1992): 9. http://dx.doi.org/10.2165/00128413-199208360-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Janssen, Rosalind. "Rosalind Janssen reviews." Journal of the Institute of Conservation 43, no. 2 (May 3, 2020): 189–91. http://dx.doi.org/10.1080/19455224.2020.1765594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Coates, L. C., E. Soriano, N. Corp, H. Bertheussen, K. Callis-Duffin, C. Barbosa Campanholo, J. Chau, et al. "OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 139–40. http://dx.doi.org/10.1136/annrheumdis-2021-eular.4091.

Full text
Abstract:
Background:Since the 2015 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably.Objectives:The goal of the GRAPPA recommendations update is to develop high quality, evidence-based recommendations for the treatment of PsA, including related conditions and comorbidities.Methods:GRAPPA rheumatologists, dermatologists and patient research partners (PRPs) updated overarching principles for the management of adults with PsA by consensus. Principles considering use of biosimilars and tapering/discontinuing of therapy were added to this update. Systematic literature searches based on data publicly available from three databases (MEDLINE, EMBASE, and Cochrane CENTRAL) were conducted from the end of the previous recommendations’ searches through August 2020. Additional abstract searches were performed for conference presentations in 2017-2020. Searches covered PsA treatments (peripheral arthritis, axial arthritis, enthesitis, dactylitis, skin, and nail disease). Additional searches were performed for related conditions (uveitis and IBD) and comorbidities evaluating their impact on safety and treatment outcomes. Individual groups assessed the risk of bias and applied the GRADE system to generate strong or conditional recommendations for therapies within the domain groups and for the management of comorbidities and related conditions. These recommendations were then incorporated into an overall treatment schema.Results:Updated, evidence-based treatment recommendations are shown (Table 1). Since 2015, many new medications have been incorporated. Additional results for older medications, such as methotrexate, have been published across PsA domains. Based on the evidence, the treatment recommendations developed by individual groups were incorporated into the overall schema including principles for management of arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease in PsA, and associated conditions (Figure 1). Choice of therapy for an individual should ideally address all of the domains that impact on that patient, supporting shared decision making with the patient involved. Additional consideration in the recommendations was given to key associated conditions and comorbidities as these often impact on therapy choice.Conclusion:These GRAPPA treatment recommendations provide up to date, evidence-based guidance to providers who manage and treat adult patients with PsA. These recommendations are based on domain-based strategy for PsA and supplemented by overarching principles developed by consensus of GRAPPA members.IndicationStrongForConditional ForConditionalAgainstStrongAgainstInsufficient evidencePeripheral Arthritis DMARD NaïvecsDMARDs, TNFi, PDE4i, IL-12/23i, IL-17i, IL-23i, JAKiNSAIDs, oral CS, IA CS,IL-6i,Peripheral Arthritis DMARD IRTNFi, IL-12/23i, IL-17i, IL-23i, JAKiPDE4i, other csDMARD, NSAIDs, oral CS, IA CS,IL-6i,Peripheral ArthritisbDMARD IRTNFi, IL-17i, IL-23i, JAKi,NSAIDs, oral CS, IA CS, IL-12/23i, PDE4i, CTLA-4-IgIL-6i,Axial arthritis, Biologic NaïveNSAIDs, Physiotherapy, simple analgesia, TNFi, IL-17i, JAKiCS SIJ injections, bisphosphonatescsDMARDs, IL-6i,IL-12/23i, IL-23iAxial PsA, Biologic IRNSAIDs, Physiotherapy, simple analgesia, TNFi, IL-17i, JAKi csDMARDs, IL-6i,IL-12/23i, IL-23iEnthesitisTNFi, IL-12/23i, IL-17i, PDE4i, IL-23i, JAKiNSAIDs, physiotherapy, CS injections, MTXIL-6i,Other csDMARDsDactylitisTNFi IL-12/23i, IL-17i, IL-23i, JAKi, PDE4iNSAIDs, CS injections, MTXOther csDMARDsPsoriasisTopicals, phototherapy, csDMARDs, TNFi, IL-12/23i, IL-17i, IL-23i, PDE4i, JAKi AcitretinNail psoriasisTNFi, IL12/23i, IL17i, IL23i, PDE4iTopical CS, tacrolimus and calcipotriol combination or individual therapies, Pulsed dye laser, csDMARDs, acitretin, JAKiTopical Cyclosporine / Tazarotene, Fumarate, Fumaric Acid Esters, UVA and UVB Phototherapy, AlitretinoinIBDTNFi (not ETN), IL-12/23i, JAKiIL-17iUveitisTNFi (not ETN)Disclosure of Interests:Laura C Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Pfizer, and Novartis, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb,GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb,GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Grant/research support from: AbbVie, Janssen, Novartis Pharma, Pfizer, Roche, and UCB, Nadia Corp: None declared, Heidi Bertheussen Consultant of: Pfizer, Kristina Callis-Duffin Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Lilly, Janssen, Novartis, Pfizer, Sienna Biopharmaceuticals, Stiefel Laboratories, UCB, Ortho Dermatologics, Inc, Regeneron Pharmaceuticals, Inc., Anaptys Bio, Boehringer Ingelheim., Cristiano Barbosa Campanholo Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Jeffrey Chau: None declared, Lihi Eder Consultant of: Abbvie, UCB, Janssen, Eli Lily, Pfizer, Novartis, Grant/research support from: Abbvie, UCB, Janssen, Eli Lily, Pfizer, Novartis, Daniel Fernandez Consultant of: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol, Grant/research support from: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol, Oliver FitzGerald Speakers bureau: AbbVie, Janssen and Pfizer Inc, Consultant of: BMS, Celgene, Eli Lilly, Janssen and Pfizer Inc, Grant/research support from: AbbVie, BMS, Eli Lilly, Novartis and Pfizer Inc, Amit Garg Consultant of: Abbvie, Amgen, Asana Biosciences, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, InflaRx, Janssen, Pfizer, UCB, Viela Biosciences, Grant/research support from: Abbvie, Dafna D Gladman Consultant of: Abbvie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Jansen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, Eli Lilly, Jansen, Novartis, Pfizer and UCB, Niti Goel: None declared, Suzanne Grieb: None declared, Philip Helliwell Speakers bureau: Janssen, Novartis, Pfizer, Consultant of: Eli Lilly, M Elaine Husni Consultant of: Abbvie, Amgen, Janssen, Novartis, Lilly, UCB, Regeneron, and Pfizer, Deepak Jadon Speakers bureau: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Arnon Katz: None declared, Dhruvkumar Laheru: None declared, John Latella: None declared, Ying Ying Leung Speakers bureau: Novartis, AbbVie, Eli Lilly, Janssen, Consultant of: Pfizer and Boehringer Ingelheim, Grant/research support from: Pfizer and conference support from AbbVie, Christine Lindsay Shareholder of: Amgen, Employee of: Aurinia pharmaceuticals, Ennio Lubrano Speakers bureau: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Consultant of: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Luis Mazzuoccolo Speakers bureau: Abbvie, Amgen, Novartis, Elli Lilly, Jansen, Consultant of: Abbvie, Amgen, Novartis, Elli Lilly, Jansen, Roland McDonald: None declared, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer, SUN and UCB, Denis O’Sullivan: None declared, Alexis Ogdie Consultant of: AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, and Pfizer, Grant/research support from: Novartis and Pfizer and Amgen, Wendy Olsder: None declared, Lori Schick: None declared, Ingrid Steinkoenig: None declared, Maarten de Wit Consultant of: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche, Danielle van der Windt: None declared, Arthur Kavanaugh Speakers bureau: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB
APA, Harvard, Vancouver, ISO, and other styles
9

Nema, Kasmir. "Intercultural Communication in the Life and Mission of Arnold Janssen." Jurnal Teologi 9, no. 2 (November 30, 2020): 187–206. http://dx.doi.org/10.24071/jt.v9i02.2620.

Full text
Abstract:
This study investigates the intercultural communication dimension of the life and mission of Arnold Janssen, the founder of the Divine Word Missionaries (SVD). This qualitative study involves a textual analysis of the relevant data and verbal descriptions of Janssen’s life and mission. The results of the study show that the seed of Janssen’s intercultural communication was primarily rooted in his parents. Being born in a family that was enveloped by a culture of prayer and a culture of peace, Janssen cultivated an intercultural sensitivity. This seed sprouted in his personality and spirituality. It revealed that Janssen was an intercultural-and-receptive person, interested in ethnic groups, cultures, beliefs, and nationalities which were different from his own. Such interests were founded by a venturesome spirit that allowed him to welcome the unfamiliarity of the other and to value such differences. The researcher finds that Janssen’s intercultural communication was contained in his practice of mission as dialogue. Through the lenses of the mission, Janssen’s dialogue competence enabled him to bridge differing views about the mission and encourage missionaries to do the same.
APA, Harvard, Vancouver, ISO, and other styles
10

Thorens, Louison, Knut Jørgen Måløy, Mickaël Bourgoin, and Stéphane Santucci. "Taming the Janssen effect." EPJ Web of Conferences 249 (2021): 08004. http://dx.doi.org/10.1051/epjconf/202124908004.

Full text
Abstract:
We investigate both experimentally and theoretically the apparent mass of a ferromagnetic granular assembly filling a cylindrical container and submitted to a magnetic field B, aligned vertically along the silo. We show that the mass of the ferromagnetic granular column depends strongly on the applied magnetic field. Notably, our measurements deviate strongly from the exponential saturation of the measured mass as a function of the true mass of the grain packing, as predicted by Janssen [H.A. Janssen, Vereins Eutscher Ingenieure Zeitschrift, 1045 (1895)]. In particular, the measured mass of tall columns decreases systematically as the amplitude of the magnetic field increases. We rationalize our experimental findings by considering the induced magnetic dipole-dipole interactions within the whole packing. We show the emergence of a global magnetic radial force along the walls of the silos, fully determined by the external magnetic field. The resulting tunable frictional interactions allows a full control of the effective mass of the ferromagnetic granular column.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Janssen"

1

Troxler, Walter. "Ein Aussenseiter der Geschichtsschreibung : Johannes Janssen 1829 - 1891 ; Studien zu Leben und Werk eines katholischen Historikers /." Berlin : Pro Business, 2007. http://deposit.d-nb.de/cgi-bin/dokserv?id=2978343&prov=M&dok_var=1&dok_ext=htm.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Skara, Brigitta, and Jens Beune. "Janssen-Cilag The communication Challenge." Thesis, Halmstad University, School of Business and Engineering (SET), 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:hh:diva-1594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Troxler, Walter. "Ein Aussenseiter der Geschichtsschreibung Johannes Janssen 1829 - 1891 ; Studien zu Leben und Werk eines katholischen Historikers." Berlin Pro Business, 2000. http://deposit.d-nb.de/cgi-bin/dokserv?id=2978343&prov=M&dok_var=1&dok_ext=htm.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Janssen, Andreas [Verfasser]. "Repräsentative Lastkollektive für Fahrwerkkomponenten / Andreas Janssen." Aachen : Shaker, 2007. http://d-nb.info/1164339257/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Schuricke, Katharina Jasmin Verfasser], Thomas [Akademischer Betreuer] Janssen, and Henning [Akademischer Betreuer] [Bier. "Knochenleitungsevozierte otoakustische Emissionen bei Neugeborenen / Katharina Jasmin Schuricke. Betreuer: Thomas Janssen. Gutachter: Thomas Janssen ; Henning A. Bier." München : Universitätsbibliothek der TU München, 2015. http://d-nb.info/1082034215/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Aydemir, Zehra Verfasser], Thomas [Akademischer Betreuer] Janssen, and Henning [Akademischer Betreuer] [Bier. "Früherkennung lärminduzierter Schwerhörigkeit mit Hilfe von Distorsionsprodukten otoakustischer Emissionen / Zehra Aydemir. Gutachter: Thomas Janssen ; Henning August Bier. Betreuer: Thomas Janssen." München : Universitätsbibliothek der TU München, 2012. http://d-nb.info/1036495183/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Agüero, Morales Ricardo Iván. "Definición modelo de compra de respuestos Janssen S.A." Tesis, Universidad de Chile, 2013. http://www.repositorio.uchile.cl/handle/2250/114030.

Full text
Abstract:
Magíster en Gestión y Dirección de Empresas
El objetivo de esta tesis es plantear el desarrollo de un modelo estratégico de compras de repuestos. El proceso de compras es de vital importancia para cualquier empresa, especialmente para una importadora y distribuidora, donde comprar a tiempo, la cantidad justa y a un precio conveniente, hace la diferencia respecto a la competencia y se transforma en una ventaja competitiva. Se propone entonces, apoyar la delicada y estresante toma de decisiones, desde un punto de vista estratégico, que recoja las inquietudes de todos los integrantes y las ordene y priorice en un modelo, que llevado a una implementación informática, soporte la toma de decisiones. La motivación surge porque en una empresa con sesenta años de vida, que ha demostrado ser exitosa, con una excelente presencia a nivel nacional y con un crecimiento sostenido, da la oportunidad perfecta para aplicar conocimientos adquiridos en este magister y aportar con una visión más actualizada para un proceso estratégico para la empresa, especialmente en un mundo globalizado como el actual. La metodología comienza determinando cuáles serían las variables principales de análisis a considerar para el modelo, recogiendo las inquietudes del Directorio, de la Gerencia General y de los ejecutivos que participan de las compras. Fue interesante, armar un prototipo y validarlo con el equipo de analistas, en forma minuciosa ítem por ítem (al menos para un conjunto representativo), lo que permite sustentar las bases de su aplicación. Se incluyen los resultados de este prototipo, aplicado al inventario actual ya permite apoyar la toma de decisiones estratégicas de compra, como por ejemplo, aplicar la estrategia de Posponer las compras en base a un tiempo de entrega real y a una mejor estimación de la demanda. Con la implementación informática del modelo, que ya lleva tres meses de operación, se ha logrado pasar de la fase de prototipo a un sistema computacional propiamente tal. Corregidos los errores típicos para este tipo de proyectos, actualmente se está en la etapa de validación de la herramienta disponible, así como de la depuración de los cálculos y estimaciones. Sin duda alguna, que esto ha permitido al equipo de especialistas disponer de más tiempo para el análisis de las distintas opciones en su proceso de compras, como el comportamiento histórico demandado por cada ítem, los cumplimientos reales por parte de los proveedores y un pronóstico de venta más acotado. Todo esto complementado con las variables extra-sistémicas que ya manejan, les permitirán enriquecer su toma de decisiones. Una evaluación preliminar permite estimar que por el sólo hecho de aplicarlo, durante el primer semestre del año en curso se debería reducir las compras en forma muy importante, lo que junto con el comportamiento de venta esperado permitirá reducir el nivel de inventario en un 25%. Esta es un objetivo muy perseguido por la empresa, puesto que permitirá liberar un importante capital de trabajo, que actualmente está inmovilizado. Se presenta un gráfico, donde muestra que los niveles de inventario en exceso han bajado desde sobre el 40% hasta un 11% aproximado para el cierre del mes de Abril. Lo que queda por demostrar, es si esta reducción del inventario no tiene contraindicaciones como quiebres de stock.
APA, Harvard, Vancouver, ISO, and other styles
8

Janssen, Stefan [Verfasser]. "Bewertung hybrid-transparenter Wärmedämmung bei Massivwandsystemen / Stefan Janssen." Aachen : Shaker, 2003. http://d-nb.info/1179019989/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Janssen, Stefan R. [Verfasser]. "Die einstweilige Verfügung im Arbeitskampf / Stefan R. Janssen." Frankfurt : Peter Lang GmbH, Internationaler Verlag der Wissenschaften, 2015. http://d-nb.info/1080458441/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pürner, Dominik Laurin [Verfasser], Thomas [Akademischer Betreuer] Janssen, Klaus-Dietrich [Gutachter] Wolff, and Thomas [Gutachter] Janssen. "Änderungen der peripheren und zentralen Schallverarbeitungsleistungen mit dem Alter / Dominik Laurin Pürner ; Gutachter: Klaus-Dietrich Wolff, Thomas Janssen ; Betreuer: Thomas Janssen." München : Universitätsbibliothek der TU München, 2019. http://d-nb.info/1188408720/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Janssen"

1

Kunsthalle in Emden, Stiftung Henri Nannen and Horst-Janssen-Museum Oldenburg, eds. Kosmos Janssen. Köln: Wienand, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Petra, Roettig, Meyer Stefanie, and Hamburger Kunsthalle, eds. Horst Janssen: Meisterzeichnungen. Hamburg: Hamburger Kunsthalle, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Horst, Janssen. Horst Janssen, Radierungen. Stuttgart: Institut für Auslandsbeziehungen, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Launay, Françoise. The Astronomer Jules Janssen. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-0697-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Michael, Phelps J. D., ed. David Janssen, my fugitive. Hollywood, Fla: Lifetime Books, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1928-, Natsume Jūrō, Tōkyō Shinbunsha, and Odakyū Gurando Gyararī, eds. Horusuto Yansen =: Horst Janssen. Tōkyō: Tōkyō Shinbun, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dierk, Lemcke, ed. Horst Janssen: Hundert Köpfe. München: Deutscher Taschenbuch-Verlag, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Horst, Janssen. Horst Janssen und Aschaffenburg. Aschaffenburg: Jesuitenkirche, Galerie der Stadt Aschaffenburg, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Heinz, Spielmann. Zwei Oldenburger Janssen-Reden. Gifkendorf: Merlin, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Horst, Janssen. Horst Janssen: Hundert Köpfe. München: Piper, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Janssen"

1

Spain, Don. "Janssen." In The Six-Inch Lunar Atlas, 47–50. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-87610-8_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Walter, Scott A., Philippe Nabonnand, Ralf Krömer, and Martina Schiavon. "Jules Janssen." In La correspondance entre Henri Poincaré, les astronomes, et les géodésiens, 163–65. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-7643-8293-3_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Starke, Klaus. "Sigurd Janssen." In Die Geschichte des Pharmakologischen Instituts der Universität Freiburg, 29–43. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18575-5_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Launay, Françoise. "Janssen and Communication." In The Astronomer Jules Janssen, 173–92. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-0697-6_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Launay, Françoise. "Janssen and Edison’s Phonograph." In The Astronomer Jules Janssen, 137–42. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-0697-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Launay, Françoise. "Janssen, the Photographic Technician." In The Astronomer Jules Janssen, 109–21. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-0697-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Barthalot, Raymonde. "Janssen, Pierre Jules César." In Biographical Encyclopedia of Astronomers, 1112–14. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4419-9917-7_713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Calvo, Emilia, Michael Saladyga, Roy H. Garstang, Raymond Mercier, Narahari Achar, Sally P. Ragep, S. M. Razaullah Ansari, et al. "Janssen, Pierre Jules César." In The Biographical Encyclopedia of Astronomers, 588–89. New York, NY: Springer New York, 2007. http://dx.doi.org/10.1007/978-0-387-30400-7_713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nath, Biman B. "Janssen, a Traveling Scientist." In Astronomers' Universe, 83–99. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4614-5363-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Launay, Françoise. "Foreword." In The Astronomer Jules Janssen, 1–7. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-0697-6_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Janssen"

1

de Boissieu, Marc. "Ted Janssen." In Aperiodic 2018 ("9th Conference on Aperiodic Crystals"). Iowa State University, Digital Press, 2018. http://dx.doi.org/10.31274/aperiodic2018-180810-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tsai, An-Pang. "Ted Janssen and Research of Aperiodic Structures in Japan." In Aperiodic 2018 ("9th Conference on Aperiodic Crystals"). Iowa State University, Digital Press, 2018. http://dx.doi.org/10.31274/aperiodic2018-180810-70.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Barsoum, A., C. Sok, S. Lee, I. Reinherz, J. Martin, and A. Adial. "Janssen Covid-19 Vaccine: Case of Thrombosis With Thrombocytopenia Syndrome in a Male Patient." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2226.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Miranda-Magalhães, Abigail, Hévellin Talita Sousa Lins, Tayonara dos Santos Melo, Tuanne dos Santos Melo, Augyna Pamyda Gomes da Silva, Maria Amélia Paiva Ferruccio, and Maria da Paz Rodrigues Silva. "ANÁLISE COMPARATIVA DA EFICÁCIA DAS VACINAS CONTRA O SARS-COV2 UTILIZADAS NO BRASIL: UMA REVISÃO INTEGRATIVA." In XXVII Semana de Biomedicina Inovação e Ciência. Editora IME, 2021. http://dx.doi.org/10.51161/9786588884119/21.

Full text
Abstract:
Introdução: No final do ano de 2019 a cidade Wuhan, na China, foi dominada pelo novo coronavírus, uma doença que provoca diversos danos respiratórios, e por isso foi denominada como Síndrome Respiratória Aguda Grave Coronavírus-2 (SARSCoV- 2)1. A transmissão deste vírus ocorre de forma extremamente rápida através dp contato direto de pessoa para pessoa, e afeta, principalmente, o sistema respiratório1. Em pouco tempo o números de casos novos e de óbito se alastrou por todo o mundo tornando a SARS-CoV-2 uma emergência de saúde pública de interesse internacional e por isso rapidamente foi declarada pela Organização Mundial de Saúde como uma pandemia, sendo também nomeada de Doença do Coronavírus 19 (COVID-19)2. Diante deste cenário, tornou-se crucial a necessidade do desenvolvimento e aplicação de vacinas eficazes contra a COVID-19. Atualmente no Brasil, estão sendo aplicadas seis tipos de vacinas: Astrazeneca, Pfizer, Janssen, Coronavac, Sputinik V e Covaxin3. Objetivo: Este trabalho visou realizar uma análise comparativa da eficácia das seis vacinas aceitas e aplicadas, até o momento, no Brasil. Métodos: Trata-se de uma revisão de literatura integrativa. Os artigos selecionados foram publicados entre janeiro de 2016 a agosto de 2021 nas seguintes bases de dados: PubMed, NCBI, Science Direct e SciELo. Para realizar o levantamento de dados foram utilizados como descritores “COVID-19 and Vacines and Brazil” e “Vacines and Efficiency and Brazil”. Resultados: A vacina Astrazeneca foi criada pelo laboratório AstraZeneca/Oxford e, atualmente, apresenta a eficácia geral de 70.42% após a segunda dose. A vacina Pfizer foi desenvolvida pelo laboratório Pfizer/BioNTech e, até o momento, apresenta a eficácia de 95% após a segunda dose. A vacina Janssen foi criada pela indústria farmacêutica Janssen da Johnson & Johnson e, atualmente, apresenta a eficácia geral de 66.1% e apenas esta, no Brasil, é de aplicação única. A vacina Coronavac foi desenvolvida pelo laboratório SinoVac e, até o momento, apresenta a eficácia de 50.38% após a segunda dose. A vacina Sputinik V foi criada pelo Instituto Gamaleya, e atualmente, apresenta a eficácia de 91.6% após a segunda dose. Por fim, a vacina Covaxin que foi desenvolvida pelo laboratório Bharat Biotech e, atualmente, apresenta a eficácia de 78.2% após a segunda dose4,5. Conclusão: Entretanto apesar da alta eficácia de todas as vacinas apresentadas ainda não é possível saber se estas induzirão memória imunológica duradoura. Portanto mais estudos são necessários para melhor compreender o efeito da vacinação contra COVID-19 a longo prazo.
APA, Harvard, Vancouver, ISO, and other styles
5

Martinez Garcia, Donaji, Kilian Gröne, Martin Fischer, Min Zhao, and Melina Bergen. "Validation of a bicycle simulator based on objective criteria." In The Evolving Scholar - BMD 2023, 5th Edition. The Evolving Scholar - BMD 2023, 5th Edition, 2023. http://dx.doi.org/10.59490/650d765b1dbdfef75c1c3a17.

Full text
Abstract:
Statistics show, that bicycles become more and more popular as transportation method, e.g. 25% increase in Germany between 2019 and 2021 (Sinus, 2021). To ensure the safety of bicycle riders as vulnerable road users (VRUs), analysing critical traffic situations is essential (Wendel, 2020). To be able to explore such situations in a safe environment, a bicycle simulator was built at DLR that can be used stand-alone or in combination with other simulators in order to integrate other traffic participants such as pedestrians or car drivers (Fischer et al., 2022; Martinez Garcia, 2021). This work describes the development of the simulator with the goal of creating a realistic and therefore immersive cycling experience (Jacobi, 2022; Janssen, 2022). A detailed description of the implementation of the recent improvements is provided as well as an objective evaluation for validation of the simulator.
APA, Harvard, Vancouver, ISO, and other styles
6

Martinez Garcia, Donaji, Kilian Gröne, Martin Fischer, Min Zhao, and Melina Bergen. "Validation of a bicycle simulator based on objective criteria." In The Evolving Scholar - BMD 2023, 5th Edition. The Evolving Scholar - BMD 2023, 5th Edition, 2023. http://dx.doi.org/10.59490/65ba5e88bfab2a7d6973cd85.

Full text
Abstract:
Statistics show, that bicycles become more and more popular as transportation method, e.g. 25% increase in Germany between 2019 and 2021 (Sinus, 2021). To ensure the safety of bicycle riders as vulnerable road users (VRUs), analysing critical traffic situations is essential (Wendel, 2020). To be able to explore such situations in a safe environment, a bicycle simulator was built at DLR that can be used stand-alone or in combination with other simulators in order to integrate other traffic participants such as pedestrians or car drivers (Fischer et al., 2022; Martinez Garcia, 2021). This work describes the development of the simulator with the goal of creating a realistic and therefore immersive cycling experience (Jacobi, 2022; Janssen, 2022). A detailed description of the implementation of the recent improvements is provided as well as an objective evaluation for validation of the simulator.
APA, Harvard, Vancouver, ISO, and other styles
7

Ateshian, G. A., W. M. Lai, W. Y. Gu, and V. C. Mow. "Ionic Polarization in Charged Hydrated Soft Tissues." In ASME 1998 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1998. http://dx.doi.org/10.1115/imece1998-0126.

Full text
Abstract:
Abstract In the development of the continuum-based macroscopic theories for charged-hydrated soft tissues (Frank and Grodzinsky, 1987; Lai et al., 1991; Gu et al., 1993, 1998; Huyghe and Janssen, 1997), as well as in the classical physical chemistry theories for electrolyte solutions (Donnan, 1924; Katchalsky and Curran, 1975, Maroudas, 1979) it is assumed that electroneutrality is satisfied at every point in the continuum, i.e., there is no net charge at any point in the material. This assumption signifies that the electric displacement is divergence free, according to Maxwell’s macroscopic equations of classical electromagnetic theory. Some studies of electromagnetic interactions in biological tissues have suggested that, consequently, the electric field should also be divergence free for the electroneutrality condition to be strictly correct (e.g., Friedman, 1986; Hart, 1988). In this abstract we review basic concepts which establish that in general the electric field is not divergence free because of ionic polarization, and we derive a general expression for calculating the equivalent polarization charge using the triphasic theory of Lai et al. (1991).
APA, Harvard, Vancouver, ISO, and other styles
8

Zheng, Xiang Yuan, and Torgeir Moan. "Freak Waves Within the Third Order Model." In ASME 2010 29th International Conference on Ocean, Offshore and Arctic Engineering. ASMEDC, 2010. http://dx.doi.org/10.1115/omae2010-20455.

Full text
Abstract:
After the New Year Wave was recorded in January 1995, considerable works have been devoted to explore the definition, physical nature and occurrence probability of freak waves. Within the frame of classical wave theories, the linear and 2nd-order random wave models have been chosen most often in the numerical simulations to study the occurrence of freak waves. This paper employs the 3rd-order random wave theory in simulation to investigate the effects of higher-order wave interaction on the freak wave occurrence. The New Year Wave is used as the case study herein. Its crest is 18.5 m, a criterion applied to categorize the simulated wave trains. To efficiently simulate a wave train with complicated wave interactions, a 1D FFT method is suggested. It is pointed out that the high values of skewness and kurtosis excess of New Year Wave cannot be captured by the 2nd-order model. The 2nd-order model is more suitable for reproducing events of high crests. Extreme events need a higher-order wave model. This work extends the study by Prevosto and Bouffandeau (2002). With totally 75,000,000 waves simulated the occurrences of freak waves of crest > 18.5 m are compared among linear, 2nd- and 3rd-order wave models. The comparative study also includes the predictions by Forristall (2000), Prevesto (2000) and the one derived based on Mori and Janssen (2004). The simulation once again reveals the inadequacy of the 2nd-order model to generate freak waves. The occurrence probability of freak waves under the 3rd-order model is more than 6 times higher than that under the 2nd-order.
APA, Harvard, Vancouver, ISO, and other styles
9

Petrova, Petya G., C. Guedes Soares, and Zhivelina I. Cherneva. "Influence of the Third Order Nonlinearity on the Distribution of Wave Height Maxima in an Offshore Basin." In ASME 2008 27th International Conference on Offshore Mechanics and Arctic Engineering. ASMEDC, 2008. http://dx.doi.org/10.1115/omae2008-58049.

Full text
Abstract:
The effect of the coefficient of kurtosis, λ40, on the distribution of wave height maxima has been investigated. The data set used consists of water surface displacements in irregular deep water unidirectional wave fields generated in an offshore basin and defined by the JONSWAP spectrum. The full-scale records are of almost 3h17min duration. The measurements have been performed at ten equidistant gauges along the basin, which permits to follow the changes in wave statistics away from the wave-generator. Subsequently, the records have been split into series of different length, corresponding to N = 100, 200 and 300 waves, and the probability density functions and the exceedance probabilities of the maximum wave heights have been constructed conditional on λ40. They have been compared with the modified Edgeworth-Rayleigh model of Mori and Janssen [1] applied to the maximum wave heights. The theoretical expressions are formulated as a simple function of the coefficient of kurtosis and the number of waves in the sample. The coefficient of kurtosis, reflecting the third order nonlinearity, is found to increase with the distance from the wave-maker. The considered theoretical density curves describe only qualitatively the shift of the empirical mode towards higher values. The tendency of the peak of the distribution to diminish with increase of λ40 has been observed. However, the most probable wave height remains underestimated by the theory for all classes of λ40, regardless of the length of the time series. Finally, the probability that a certain normalized height level Hmax/Hs will be exceeded increases with the increase of λ40, as being theoretically predicted, although it is overestimated by the theory in the lower range of values of λ40 and underestimated over the higher range of values of λ40.
APA, Harvard, Vancouver, ISO, and other styles
10

De Clerck, F., R. Van de Wiele, B. Xhonneux, L. Van Gorp, Y. Somers, W. Loots, J. Beetens, J. Van Wauwe, E. Freyne, and P. A. J. Janssen. "PLATELET TXA2 SYNTHETASE INHIBITION AND TXA2/PROSTAGLANDIN ENDOPEROXIDE RECEPTOR BLOCKADE COMBINED IN ONE MOLECULE (R 68070)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643465.

Full text
Abstract:
F 68070, an oxime-alkane carboxylic acid derivative (Janssen Pharmaceutica), is a potent inhibitor of thromboxane A2 (TXA2) synthetase activity (IC50 in vitro against thrombin-stimulated human platelets in plasma : R 68070 : 2.9 x 10-8 M; CGS 13080 : 6 x 10-8 M; OKY-1581 : 8.2 x 10-8 M; dazmegrel : 2.6 x 10-8 M; dazoxiben : 2.3 x 10-8 M).The compound specifically inhibits platelet TXA2 synthetase activity (14C-arachidonic acid metabolism by washed human platelets) without effect on the cyclo-oxygenase, lipoxygenase (platelets, RBL cells) or prostacyclin synthetase activities (rat aortic rings).The inhibitory effect of R 68070 against human platelet TXA2 synthetase activity increases upon prolongation of the contact time (ICsg at 0.5 min of contact : 5.2 x 10-7 M; at 5 min : 8.3 x 10-8 M; at 30 min : 2.5 x 10-8 M) and is reversed by washing of the platelets.In vivo, the compound has a comparatively strong inhibitory effect on platelet TXA2 synthetase activity after oral administration to rats (ED50 - 2 h : R 68070 0.013 mg/kg; CGS-13080 : 0.8 mg/kg; OKY-1581 : 0.61 mg/kg; dazmegrel : 1 mg/kg; dazoxiben : 4.1 mg/kg) and a protracted duration of action in rats and dogs (inhibition 8 h after 1.25 mg/kg orally > 80 %).In vitro, R 68070 inhibits the aggregation of human platelets in plasma stimulated with collagen (IC50 : 4 x 10-6 M), but also with U 46619 (IC50 : 3.8 x 10-6 M) without affecting the primary aggregation reaction elicited by ADP, 5-HT or adrenaline. The compound thus also produces platelet TXA2/prostaglandin endoperoxide receptor blockade.In rats and in dogs R 68070 (1.25 mg/kg I.V.) potently prevents thrombus formation in carotid and coronary arteries damaged by electrical stimulation.The combination of platelet TXA2 synthetase inhibition with TXA2/prostaglandin endoperoxide blockade in one molecule thus might offer an improved anti-thrombotic effectiveness.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Janssen"

1

Microenterprise Development Review: Volume 5 : No. 1 : August, 2002. Inter-American Development Bank, August 2002. http://dx.doi.org/10.18235/0008389.

Full text
Abstract:
The first article of this edition of the Microenterprise Development Review examines the relationship between microfinance institutions and private international investors. This article is written by Robert Pouliot of RCP & Partners, a Swiss-based fiduciary agency based in Switzerland and Germany. The second article addresses microfinance regulation in Latin America and the Caribbean and is written by Tor Jansson, a Microenterprise Specialist in the Micro, Small and Medium Enterprise Division of the Inter-American Development Bank.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Janssen' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography